MOUNTAINSIDE, NJ--(MARKET WIRE)--Aug 25, 2008 -- National Stem Cell Holdings, Inc. (Other OTC:PROTD.PK - News) announces that it has changed its name to Proteonomix, Inc. (the "Company"), its trading symbol from NHGI to PROTD (the "Company") and 10:1 reverse split of its outstanding common stock and convertible preferred stock.

The new name and symbol reflect Proteonomix's core focus on proteomics (the large-scale study of proteins, particularly their structures and functions) and the identification and commercialization of new proteins for use in therapeutics and cosmetics. The name change marks Proteonomix's turning point, from an R&D only company to a company which combines commercial product development and R&D. Proteonomix plans to commercialize its proprietary cell expansion line this year. The Company's multi-faceted R&D program has demonstrated results with more than ten patent applications and multiple products ready to enter the market. Additionally, The Company introduced its new cosmoceutical product line, through its subsidiary, Proteoderm, Inc., in July 2008.

Proteoderm plans to scale its proprietary proteins, derived from non-embryonic stem cells, into an extensive array of specialty skin care products. Thus far, Proteoderm has received encouraging response during the first public display of its skin care products at the recent International Anti-aging Conference in Washington D.C. For a full description of Proteoderm's skin care products, visit www.proteoderm.com.

The Board of Directors authorized a 10 to 1 reverse stock split on all issued common and convertible preferred stock. Management believes that the new corporate restructure, together with the name change, will position Proteonomix to raise capital in this very challenging financial environment for product commercialization and should enhance shareholder value by positioning Proteonomix for return to OTCBB market.

The Company will continue to keep shareholders notified on continuing progress at the next shareholders meeting for the fourth quarter of this year.

About Proteonomix, Inc.

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Its investigational products are designed to improve the quality of life for patients. The Company is developing an intellectual property portfolio in cosmoceutical products based on its recent discovered and isolated "Secreted Matrix." For more information please visit www.Proteonomix.com.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

     Contact:
     Michael Cohen
     #973-544-6116
     Email Contact